<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01570829</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-DI-003</org_study_id>
    <nct_id>NCT01570829</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Safety and Efficacy of New Dosage Schedule for Dietressa Drug in Treatment of Obese Patients</brief_title>
  <official_title>Multicentric Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Safety and Efficacy of New Dosage Schedule for Dietressa Drug in Treatment of Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To assess safety of Dietressa in the dose of 6 tablets daily within 24 weeks in
           treatment of obese patients (BMI 35,0-39,9 kg/m2).

        -  To assess clinical efficacy of Dietressa in the dose of 6 tablets daily within 24 weeks
           of therapy in reducing body weight in obese patients (BMI 35,0-39,9 kg/m2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In general, patients will be observed during 24 weeks of trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with body weight reduction by 5 percent and more after 24 weeks of treatment</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average body weight reduction (absolute and relative) after 24 weeks of treatment</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with body weight reduction by 5 percent and more after 4, 8, 12, 16 and 20 weeks of treatment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average body weight reduction (absolute and relative) after 4, 8, 12, 16 and 20 weeks of treatment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference, waist circumference to thigh circumference ratio after 4, 12 and 24 weeks of treatment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamics of the quality of life according to the data of SF-36 questionnaire after 4, 12 and 24 weeks of treatment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">332</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Dietressa (1 tablet 6 times daily)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (1 tablet 6 times daily)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dietressa</intervention_name>
    <description>Safety and Efficacy of New Dosage Schedule</description>
    <arm_group_label>Dietressa (1 tablet 6 times daily)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Safety and Efficacy of New Dosage Schedule</description>
    <arm_group_label>Placebo (1 tablet 6 times daily)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Outpatient subjects with BMI 35,0-39,9 kg/m2.

          2. Male or female subjects aged 18 to 65 inclusive.

          3. Use of and compliance with contraception methods by patients of reproductive age, of
             both sexes.

          4. Presence of the patient's information sheet (informed consent form) for participation
             in the clinical trial.

        Exclusion Criteria:

          1. Symptomatic (secondary) obesity:

               -  with established genetic defect (including as a part of known genetic syndromes
                  affecting multiple organs): Prader-Willi syndrome, Alstrom's syndrome,
                  Laurence-Moon-Biedl syndrome, Dercum's syndrome etc.

               -  cerebral (adiposogenital dystrophy, Babinski-Frohlich syndrome): brain tumors;
                  dissemination of systemic lesions, infectious diseases; against mental diseases.

               -  endocrine: hypothyroid; hypoovarial; pituitary-hypothalamic disorders;
                  adrenopathy.

               -  iatrogenic (caused by drug administration, namely, insulin, glucocorticosteroids,
                  neuroleptics etc.).

          2. Compliance with a diet prescribed and monitored by the doctor to reduce body weight
             within 6 months before enrollment.

          3. Participation in the lifestyle modification program within 6 months before enrollment.

          4. Patients who quit smoking within 6 months before enrollment, or intending to quit
             smoking during the period of participation in the trial, as well as intending to begin
             smoking during the trial.

          5. Uncontrolled arterial hypertension (patients with 1-3 degree AH, receiving no adequate
             antihypertensive therapy).

          6. Type 1 and 2 diabetes mellitus.

          7. Edema syndrome with various etiology (chronic cardiac failure, nephrotic syndrome,
             hepatic cirrhosis).

          8. Circulatory failure, II–ê degree and above.

          9. Decompensated cardiovascular disease, liver, kidney or gastrointestinal tract disease,
             metabolic, respiratory, endocrine, hematologic disease, peripheral vessel disease or
             another medical state. Oncological disease.

         10. Diseases and states, which, in the investigator's opinion, may prevent the patient
             from participating in the trial.

         11. Past history of bulimia / non-drug abepithymia.

         12. Past history of any bariatric surgeries.

         13. Lipoplasty underwent less then 1 year prior to screening visit, or cavitary surgery
             less then 6 months prior to screening visit.

         14. Surgeries scheduled within 6 months.

         15. Allergy to/intolerance of any of the drug components used during treatment.

         16. Malabsorption syndrome, including congenial or acquired lactase or another
             disaccharidase insufficiency.

         17. Administration of drugs specified as &quot;Prohibited concomitant therapy&quot;, within 6 months
             before enrollment.

         18. Pregnancy, breast-feeding, unwillingness to comply with contraception methods during
             the trial and within 30 days after completion of participation in the trial.

         19. Drug and alcohol consumption (over 2 alc. units daily), mental diseases. Legal
             incapacity or limited legal capacity.

        21. Patients, who, in the investigator's opinion, will fail to observe the requirements
        during the trial or adhere to the studied drug administration procedure.

        22. Participation in other clinical trials within 3 months before enrolment in this trial.

        23. Presence of other factors, complicating the patient's participation in the trial (e.g.,
        planned lengthy business and other trips). 24. A patient is a part of the center's research
        staff, taking a direct part in the trial, or an immediate family member of the
        investigator. Immediate family members are defined as spouses, parents, children or
        siblings, regardless of whether full blood or adopted.

        25. The patient is employed with Scientific Production Firm Materia Medica Holding LLC,
        i.e. is the company's employee, part-time employee under contract, or appointed official in
        charge of the trial, or their immediate family.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The State Educational institution of High Professional Training Kuban State Medical University of Ministry of Health Care and Social Development of the Russian Federation, Department of Clinical Pharmacology</name>
      <address>
        <city>Krasnodar</city>
        <zip>350063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Educational institution of High Professional Training I.M. Sechenov First Moscow State Medical University of Ministry of Health Care and Social Development of the Russian Federation, Endocrinology Faculty</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Budget Health Care institution of Moscow the City Clinical Hospital No. 11 of the Administration of Health Care of Moscow City</name>
      <address>
        <city>Moscow</city>
        <zip>127018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Medical and Preventive institution &quot;City Clinical Hospital No.10&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Budget Health Care institution of Nizhegorodskyi Region &quot;Nizhegorodskaya Regional Clinical Hospital n.a. N.A.Semashko&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Educational institution of High Professional Training &quot;Rostov State Medical University&quot; of Ministry of Health Care and Social Development of the Russian Federation, Department of Endocrinology</name>
      <address>
        <city>Rostov na Donu</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Health Care institution &quot;Municipal Hospital No.6&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191482</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Health Care institution &quot;Municipal Hospital No.77 of Nevsky District&quot;, The City Diabetes Center</name>
      <address>
        <city>St. Petersburg</city>
        <zip>192177</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Federal State Health Care institution L.G. Sokolov Memorial Hospital No. 122 of the FMBA (Federal Medical and Biological Agency).</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Educational institution of High Professional Training &quot;St. Petersburg State Medical University n.a. I.P. Pavlov of the Federal Agency for Health Care and Social Development&quot;, Therapy Faculty Board</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg state Health Care institution &quot;Saint Venerable Martyr Elizaveta Municipal Hospital&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Health Care institution &quot;Consultative and Diagnostic Center No. 85&quot;, Diabetes Center</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198260</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Educational institution of High Professional Training &quot;St. Petersburg State Medical University n.a. I.P. Pavlov of the Federal Agency for Health Care and Social Development&quot;, Faculty Surgery Board</name>
      <address>
        <city>St.Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Educational institution of High Professional Training &quot;Bashkirsky State Medical University&quot; of the Federal Agency for Health Care and Social Development, Department of Endocrinology</name>
      <address>
        <city>Ufa</city>
        <zip>450000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Educational institution of High Professional Training &quot;Volgograd State Medical University&quot; of Ministry of Health Care and Social Development of the Russian Federation</name>
      <address>
        <city>Volgograd</city>
        <zip>400131</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Health Care institution &quot;Voronezh Regional Clinical Consultative &amp; Diagnostic Center&quot;</name>
      <address>
        <city>Voronezh</city>
        <zip>394018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Health Care institution of Yaroslavl Region the Clinical Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2012</study_first_submitted>
  <study_first_submitted_qc>April 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2012</study_first_posted>
  <last_update_submitted>December 25, 2017</last_update_submitted>
  <last_update_submitted_qc>December 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

